AI-guided antibody design platform pairing machine learning with a wet lab
BigHat Biosciences designs antibody therapeutics by coupling ML models built in Python and PyTorch with an automated lab running Opentrons and Tecan robotics, LC-MS and HPLC. A Clinical Operations Director search, IND-enabling studies and oncology and inflammatory trials show a shift from platform company toward clinical-stage developer. A QuickBooks-to-NetSuite move plus public-company compliance prep point to finance infrastructure being built for scale.
Notable leadership hires: Clinical Operations Director
BigHat Biosciences is a privately held biotech company founded in 2019 and headquartered in San Mateo, California, with 51–200 employees. It develops protein therapeutics, specifically antibodies, using a platform that combines high-throughput experimental characterization with machine learning to speed engineering. The software layer runs on AWS serverless and container services with PostgreSQL, while lab work relies on LIMS, liquid-handling robotics and analytical chemistry instruments. Hiring is concentrated in the United States and weighted toward research and data roles.
BigHat uses Python, PyTorch, Pandas and SQLAlchemy on AWS (Lambda, Step Functions, ECS, Fargate, CDK, Athena) with PostgreSQL, a TypeScript/React front end, plus LIMS, Opentrons, Tecan and LC-MS in the lab.
Yes, hiring is accelerating and US-based, led by senior research scientists and data roles, with additional openings in finance, operations and clinical operations leadership.
Current work includes generative models of antibody sequence and structure, automating its design-build-test loop, high-throughput developability assays, IND-enabling studies and early-phase biologics trials in oncology and inflammatory disease.
Other companies in the same industry, closest in size
BigHat Biosciences's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.